IMU-838 could be alternative treatment option for RRMS patients ineligible with mAbs

In the randomised, double-blind, placebo-controlled, multicentre Phase II trial, EMPhASIS, IMU-838 achieved all primary and key secondary endpoints. Credit: Shutterstock + Miriam Doerr Martin Frommherz.



  • rrms